Renal Assist Device (RAD) for Patients With Renal Insufficiency Undergoing Cardiac Surgery

NCT ID: NCT05990660

Last Updated: 2024-01-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-09-28

Study Completion Date

2024-01-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is a prospective, non-randomized early feasibility study intended to evaluate the safety and performance of the JuxtaFlow System (also known as the JuxtaFlow Renal Assist Device (RAD)) in participants with pre-existing renal insufficiency who are undergoing cardiac surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The BIPASS-AKI study is intended to evaluate participants who are at an increased risk of developing cardiac surgery-associated acute kidney injury (CSA-AKI), and, subsequently, overall poor outcomes. Patients to be considered for participation include those undergoing elective or urgent in-house on-pump cardiac surgery (to include coronary artery bypass graft, valvular surgery, or combination) and have pre-existing renal insufficiency as defined by a pre-operative eGFR between 15-60 mL/min. Participants meeting inclusion and exclusion criteria will be enrolled into a treatment arm (single-arm study) following the completion of informed consent. Participants will receive implantation of the JuxtaFlow Catheters following completion of the their cardiac surgery while remaining under anesthesia. Treatment with the JuxtaFlow System will be initiated upon the participant's arrival into the intensive care unit and continue for up to 24 hours post-operatively. Preoperative, intra-operative, and post-operative data will be collected on participants to include 15- and 30-day follow-up periods.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Insufficiency Acute Kidney Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

BIPASS-AKI is a single-arm, unblinded interventional study designed to assess the safety of the JuxtaFlow System.
Primary Study Purpose

DEVICE_FEASIBILITY

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment

Group Type EXPERIMENTAL

JuxtaFlow System

Intervention Type DEVICE

Mild, controlled negative pressure introduced into the renal pelvis via JuxtaFlow catheters

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

JuxtaFlow System

Mild, controlled negative pressure introduced into the renal pelvis via JuxtaFlow catheters

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Candidate cardiac surgical patients
2. Elective or Urgent on-pump coronary artery bypass grafting (CABG) and/or valvular surgery
3. Age 22 to 85 years
4. eGFR \< 60 mL/min/1.73m2
5. Signed informed consent

Exclusion Criteria

1. End-stage renal disease (receiving hemodialysis or glomerular filtration rate \<15 ml/min/1.73m2)
2. Planned off-pump surgery
3. Any patients with high-grade proteinuria (i.e., urine protein concentration \> 300 mg/dL)
4. Pregnancy
5. Any secondary condition as determined by the investigator that would place the subject at an increased risk, or preclude the subject's full compliance with the study procedures, including injuries to the urinary organs and/or external genitals
6. Current or planned treatment with an investigational drug (IND), device (IDE), or other investigational intervention within 3 months prior to or during participation in this clinical trial
Minimum Eligible Age

22 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

SCIRENT

UNKNOWN

Sponsor Role collaborator

3ive Labs

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Slobodan Micovic, MD

Role: PRINCIPAL_INVESTIGATOR

Institute for Cardiovascular Diseases Dedinje

Milovan Petrovic, MD

Role: PRINCIPAL_INVESTIGATOR

Institute of Cardiovascular Diseases of Vojvodina

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Polsko-Amerykanskie Kliniki Serca, Centrum Kardiologii

Krakow, Bielsko-Biata, Poland

Site Status

Institute for Cardiovascular Diseases "Dedinje"

Belgrade, , Serbia

Site Status

Institute of Cardiovascular Diseases of Vojvodina

Kamenitz, , Serbia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Poland Serbia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RAD1117-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.